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ABSTRACT - Purpose. Codeine containing medicines can carry a number of health risks associated with the 
increase in reported misuse and dependence, however they are still readily available over the counter (OTC) in 
many countries. The aim of this novel study was to report on the results of a survey of customers purchasing OTC 
codeine containing medicinal products at pharmacies in Ireland, South Africa and England; exploring use, sources 
of knowledge and perception of risks. Methods. The study design was an exploratory cross sectional survey. It 
involved a customer self-administered questionnaire at the point of purchase (n=1230).  Relationships between 
categorical variables were analysed using Pearson chi-square for bivariate analysis. Continuous scale variables 
were analysed using one way analysis of variance. Results. In Ireland 6% stated they purchased codeine containing 
products weekly, in South Africa 13% and in England 16%. In Ireland and England women are more likely to view 
codeine containing products as harmful. In England older adults are more likely to perceive codeine containing 
products as harmful. A higher proportion of customers in South Africa opposed restricting codeine containing 
products to prescription only when compared with people in Ireland and England. Conclusions. Codeine 
containing products are widely purchased and used in all three jurisdictions. Whilst the majority of customers 
appear to have some awareness and knowledge of risks, it does not materially impact on their purchasing behaviour 
with a substantial minority purchasing/using such products on a weekly basis. This regularity of purchase whilst 
indicative of the popularity of such products, may also be a potential indicator of misuse. Future research is needed 
in relation to cultural and gendered differences and targeted information giving and harm reduction initiatives for 
safe usage of these medicinal products. 
______________________________________________________________________ 
 
INTRODUCTION 
 
Codeine (3-methylmorphine) is a weak opioid, 
widely used for its analgesic, antitussive and anti-
diarrheal properties. Commonly used to manage 
mild to moderate pain, it is available in low dose 
non-prescription medicinal products in a number of 
countries (1-2). Over the counter (OTC) purchase of 
codeine based analgesic products without medical 
consultation occurs in many countries and even in 
countries where it is regulated, purchase and use is 
considerable (3).  There is little comparative 
international data exploring differences in customer 
use, sources of information and knowledge of OTC 
codeine containing products between countries 
which allow non-prescription purchase. This paper 
reports on a study that aimed to address this gap 
through a survey of customers purchasing such 
products at participating community/ commercial 
outlet pharmacies in Ireland, South Africa and 
England. 
 
 
 
Deregulation has led to increased customer 
access, choice, self-medication and pharmacist 
empowerment with regards to codeine and non-
opioid analgesic dispensing (4,5,6). Consequently, 
the misuse of these products appears to be on the 
increase (2,7); with access to open purchase 
lessening the consumers’ ability to recognise 
problematic use and dependency (9-10). Public 
perception and possibilities for opioid tolerance 
within a short timeframe contributing to habitual use, 
misuse and dependence (8). Awareness of the 
dangers associated with these products is somewhat 
mixed. Bower and colleagues found that consumers 
tended not to approach the use of OTC medicines 
with the same level of caution and care as they 
displayed towards prescribed medication. (11). 
________________________________________ 
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Research indicates OTC analgesics and other 
codeine based medicinal products are frequently 
taken inappropriately and that consumers are 
generally unaware of the potential of the physical 
harms that can result (12-14, 4).    However, there is 
some evidence which suggests that public awareness 
of harm risks is improving (15-16). 
Direct to consumer advertising (DTCA) is a 
significant avenue through which pharmaceutical 
companies promote medicinal products to 
consumers (17-19). DTCA creates product 
awareness and encourages use amongst consumers. 
DTCA empirical research in relation to medicinal 
products is not extensive and tends to focus on 
national rather than international contexts. The 
available studies indicate that DTCA can be a 
significant source of information and is highly 
influential in relation to consumer choice of product, 
use of such products and belief in product safety (19-
21); particularly if the product is regularly and 
widely advertised (22-25).  DTCA can also be a 
considerable source of tension between the 
consumer and professional pharmacists (26), as 
consumers appear to trust and pay attention to DTCA 
messages rather than the informed opinion of 
pharmacists encountered at the point of purchase 
(25-29). 
 
METHODS 
 
Study Design 
This study adopted an exploratory, cross sectional 
design, involving a self-administered questionnaire 
to collect data from consumers at the point of 
purchase with a purposive sample who, at the time of 
survey, purchased OTC medicinal products in 
pharmacies in Ireland; South Africa and England. 
Customers who were aged 18 or over and were able 
to read in English were asked to participate.  Thirty-
six questionnaires contained too many missing 
values and were therefore excluded from analysis.  
Hence the final sample consisted of 1230 customers 
across all three countries.  Ethical approval was 
received in August 2016 from research institutions in 
Ireland; South Africa and England. 
 
Questionnaire development 
The questionnaire, based on previously published 
literature, was assessed for content validity by the 
research team (academic researchers and experts in 
pharmacology, addiction and pharmacovigilance). 
Pilot testing was conducted in three outlets to test the 
survey form. Following on from this pilot, some 
items were changed and the overall number of items 
reduced. 
The final 18 item questionnaire consisted of 
closed-, open-ended and Likert scale response items 
covering demographics; use of OTC codeine 
containing medicines; purchasing patterns of such 
products; views on their safety and availability. The 
survey was anonymous and no individuals could be 
identified through their responses. 
 
DATA ANALYSIS 
 
The statistical package SPSS v.22 was used for 
analyses. To examine relationships with other study 
variables, the demographic variables of gender; 
marital status; age; education and employment status 
were treated as categorical data. Variables relating to 
the use of OTC codeine containing products and 
knowledge pertaining to where to purchase such 
medicines were also treated as categorical data. 
Relationships between these variables were analysed 
using standard statistical methods for categorical data 
– Pearson chi-square for bivariate analysis. 
The questionnaire’s final section contained 5 
closed-ended statements, measured on a Likert scale. 
The data was treated as continuous and each category 
was recoded to indicate positive or negative 
agreement with each of the statements. This 
produced a scale of +2 to –2 where +2 showed the 
strongest agreement and -2 indicated the strongest 
disagreement. Neutral responses were scored as 0. 
Consequently, the data was analysed mainly using 
parametric methods. Adjoining categories within 
these items were collapsed; strongly agree and agree 
were combined; neutral was treated as a separate 
category and finally, disagree and strongly disagree 
were also merged. The percentage agreement and 
frequencies were then presented as an indication of 
the overall level of agreement with the statements. 
Additionally, these variables were subsequently 
treated as categorical and were analysed by Pearson 
chi-square and the results were then compared. 
 
RESULTS 
 
Profile of respondents 
Demographics for each country are presented in 
Table 1.  
 
Use of Codeine containing products medicine 
The majority of respondents took codeine containing 
medicines to treat pain; however 2% in Ireland and 
0.5% in England took these medicines to help them 
to relax, compared to 6% in South Africa (Fig. 1). 
In both Ireland and England the proportion of 
males (77%, 70%) who had taken codeine containing 
medicines was not significantly different to females 
(81%, 80%). However, a difference was seen in 
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South Africa, where 74% of males took these 
medicinal products compared to 79% of females and 
there was a significant association between gender 
and use of Codeine containing products medicine 
(χ2(2, n=665) = 6.40, p=0.04, phi=0.10).  
Nineteen percent and 15% of respondents in 
Ireland and England indicated they did not read the 
information leaflet, whereas in South Africa this 
figure was roughly a third at 29% (Table 2). Chi-
square test for independence indicated a significant 
association between country and reading advice 
(χ2(4, n=1027) = 25.60, p=0.00, phi=0.16). There 
were no statistically significant results in terms of 
gender and reading advice; however in all three 
countries the proportion of females reading the 
advice was always higher than for males. 
A significantly higher proportion of English 
respondents (94%) stated they consumed 
combination codeine containing analgesics (χ2(4, 
n=1020) = 94.81, p=0.00, phi=0.31). Furthermore, 
English respondents (80%) seemed more aware of 
the warnings associated with paracetamol packaging 
(χ2(2, n=297) = 16.28, p=0.00, phi=0.23).  
The majority of Irish respondents (42%) took 
codeine containing products less than once a month 
(Fig. 2). In South Africa, 17% took such products a 
couple of times a week and 17% stated less than once 
a month. In England, 26% of respondents stated they 
consumed these products less than once a month but 
this was followed closely by 22% who stated at least 
a couple of times a week.  
In all three countries, respondents stated 
constipation, drowsiness and nausea among the 
unpleasant side effects. In South Africa, these also 
included dizziness and dependence. In England side 
effects included dizziness and headache. All three 
countries were very similar in relation to the 
proportion that had experienced these unpleasant side 
effects (12% in Ireland, 14% in South Africa and 
16% in the U.K.). 
 
Table 1. Demographic profile of respondents 
N=1230 Ireland a 
(N=328) 
South Africa a 
(N=665) 
England a (N=237) 
 n % n % n % 
Gender       
Male     80 25 266 42 95 41 
Female 243 75 374 58 139 59 
Age       
Over 18 
21-30 
26 
86 
8 
27 
44 
141 
7 
21 
8 
57 
3 
24 
31-40 
41-50 
77 
66 
24 
20 
164 
141 
25 
21 
40 
44 
17 
19 
51-60 
61-70 
71 and over 
44 
21 
5 
14 
6 
1 
92 
47 
31 
14 
7 
5 
40 
27 
19 
17 
12 
8 
Marital status       
Married/living with partner 174 54 359 56 137 59 
Never married 107 33 163 25 45 19 
Divorced / Separated 
Widowed 
21 
19 
7 
6 
78 
43 
12 
7 
32 
18 
14 
8 
Education       
Primary School 10 3 16 2 4 2 
Secondary / High School 105 32 360 55 109 47 
College 209 65 279 43 120 51 
Employment status        
Employed 231 71 483 73 141 60 
Unemployed 
Homemaker 
Student 
Unable to work due to a chronic condition 
Retired 
21 
29 
20 
7 
18 
6 
9 
6 
2 
6 
48 
36 
29 
8 
55 
7 
6 
5 
1 
8 
30 
14 
7 
4 
39 
13 
6 
3 
2 
16 
a Some percentages calculated using denominator less than stated total due to missing data 
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Figure 1. Reasons cited for taking codeine containing products 
 
 
Table 2. Advice and warnings 
N=1027 Ireland South Africa England 
 n % 
 
n % n            % 
Read advice***       
Yes 
No  
Don’t know 
216 
54 
7 
78 
19 
3 
 
390 
161 
11 
69 
29 
2 
 
150 
27 
11 
80 
15 
5 
Used combination analgesic***       
Yes 
No  
Don’t know 
173 
58 
41 
64 
21 
15 
306 
164 
90 
55 
29 
16 
176 
5 
7 
94 
2 
4 
 
Notice paracetamol warning*** 
         
Yes 
No  
Don’t know 
99 
41 
12 
65 
27 
8 
__ 
__ 
__ 
__ 
__ 
__ 
116 
13 
16 
80 
9 
11 
***p < 0.001 
 
 
In relation to the purchase of Codeine containing 
products, in Ireland, 65% stated that they purchased 
these products in the local pharmacy; a higher 
percentage (73%) stated the same in South Africa. 
However, in England the percentage was only 45% 
(Table 3). In Ireland and England, 1% and 2% 
respectively stated they purchased these products 
every day; however in South Africa this was 5%. In 
Ireland 6% stated they purchased weekly, in South 
Africa 13% and in England 16%. Medicines 
purchased most frequently in Ireland included 
Nurofen Plus ®, Solpadeine ® and Feminex ®. 
Medicines purchased most frequently in South Africa 
included Adcodol ® and Benylin ®. Medicines 
purchased regularly in England included Co-
codamol ®, Nurofen ® and Solpadeine ®. 
 
Knowledge of codeine containing products  
Respondents were asked to state their main sources 
of information in relation to medicine containing 
codeine. In all three countries, the most frequent 
answer was from the physician or pharmacist (Fig. 
3). However, this was followed by advice from 
family and friends in both Ireland (23%) and South 
Africa (26%). In England, 27% stated they sourced 
their information from the packaging or leaflet.  
0 10 20 30 40 50 60 70 80 90
Pain
Cough
Sleep
Relax
Other
Frequency of items as a percentage of participants in each country (%)
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Figure 2. Frequency of use in the last year 
 
 
To a statement concerning effectiveness, the 
majority in all three countries agreed that it is 
effective (Table 4; 79% v 73% v 80%). Only, 34% of 
respondents in Ireland, 43% in South Africa and 25% 
in England disagreed with the statement that codeine 
containing medicines should be prescription only. In 
Ireland and England a similar proportion agreed that 
these medicines were harmful and addictive. 
However, in South Africa the proportion was lower. 
A one-way between-groups analysis of variance and 
a chi-square test were conducted and revealed a 
statistically significant difference between countries 
(p=0.00), post hoc analysis indicated that South 
Africa was significantly different to both Ireland and 
England for both statements. 
An independent-samples T-Test was used to 
compare gender against areas of knowledge. In 
Ireland, this was statistically significant for 
prolonged use of such products is harmful (p=0.000) 
and medicine containing codeine is addictive 
(p=0.000). In both of these areas females agreed to a 
greater extent with the statements compared with 
males.   In England, females appeared to agree more 
strongly than males that prolonged use of codeine 
containing products is harmful (p=0.026) and that 
such products are addictive (p=0.022). However, 
when a Chi-square test for independence was run 
using the categorical data from England, no 
significant association was identified. 
Impact of age was explored on knowledge of 
codeine containing products. In England, there was a 
statistically significant difference in relation to the 
statements that prolonged use of codeine containing 
products is harmful (p=0.001) and that medicine 
containing codeine is addictive (p=0.000). The 41-50 
(p<0.00) and 61-70 (p<0.05) age groups agreed more 
strongly with the first statement compared to the 21-
30 age group. Similarly, the 41-50 (p<0.00) and 51-
60 (p<0.01) age groups agreed with the second 
statement more than the 21-30 age group.  
Level of education was compared against areas 
of knowledge of medicinal products containing 
codeine. In Ireland, this was statistically significant 
for prolonged use of codeine containing products is 
harmful (p=0.01) and medicine containing codeine is 
addictive (p=0.04). Those with college or a technical 
background agreed to a greater extent with the 
statements compared with those who completed 
secondary school (p<0.01 and p<0.05). In South 
Africa, those educated to college level appeared to 
agree more strongly, compared to those who had 
completed secondary level education, that medicine 
containing codeine should be available on 
prescription only (p=0.02); that prolonged use of 
codeine containing products is harmful (p=0.01) and 
that medicine containing codeine is addictive 
(p=0.05).  
 
 
0 5 10 15 20 25 30 35 40 45
Every day
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Once a week
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Table 3. Purchase of medicine containing codeine containing products 
 Irelanda 
(N=328) 
South Africaa  
(N=665) 
England (N=237) a 
 n % n % n % 
Purchased in the last year 
Yes 
No  
Don’t know 
Where do you purchase 
Local pharmacy 
Supermarket 
The internet 
Other 
Frequency of purchase 
Every day 
Weekly 
Monthly 
Very occasionally 
Never buy it 
Don’t know 
 
 
202 
84 
34 
 
212 
16 
1 
0 
 
2 
13 
52 
136 
6 
8 
 
63 
26 
11 
 
65 
5 
0.3 
0 
 
1 
6 
23 
63 
3 
4 
 
471 
163 
0 
 
487 
--- 
3 
9 
 
27 
65 
158 
206 
6 
37 
 
74 
26 
0 
 
73 
--- 
0.5 
1 
 
5 
13 
32 
41 
1 
8 
 
115 
101 
21 
 
107 
29 
0 
0 
 
2 
20 
27 
68 
3 
2 
 
48 
43 
9 
 
45 
12 
0 
0 
 
2 
16 
22 
56 
3 
1 
a Some percentages calculated using denominator less than stated total due to missing data 
 
 
 
 
Figure 3. Sources of Information 
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Table 4. Knowledge relating to codeine containing products 
 
 
 
 
Statements 
Irelanda 
(N=328) 
 
Mean (±SD) 
n (%) 
 
South Africaa 
 (N=665) 
 
Mean (±SD) 
n (%) 
 
Englanda  
(N=237) 
 
Mean (±SD) 
n (%) 
Medicine containing codeine is effective 1.12 (0.84) 
251 (79) 
0.97 (0.97) 
437 (73) 
0.96 (0.71) 
177 (80) 
Medicine containing codeine is safe to 
use 
 
0.53 (0.90) 
177 (58) 
0.52 (1.0) 
310 (52) 
0.51 (0.90) 
114 (54) 
Medicine containing codeine should be 
available on prescription only 
 
0.02 (1.16) 
99 (32) 
-0.21 (1.30) 
180 (30) 
0.21 (1.11) 
84 (39) 
Prolonged use of medicine containing 
codeine is harmful 
 
0.98 (0.96) 
210 (67) 
0.57 (1.11) 
271 (45) *** 
0.82 (0.92) 
133 (62) 
Medicine containing codeine is addictive 
 
0.91 (0.97) 
195 (63) 
0.39 (1.05) 
315 (52) *** 
0.80 (0.96) 
127 (60) 
***p < 0.001   
a Some percentages calculated using denominator less than stated total due to missing data 
 
DISCUSSION 
 
The literature indicates that patients develop an 
iatrogenic codeine dependence as a result of initially 
taking this medication to manage pain; the literature 
also indicates that others commence using it to 
manage stress, anxiety or help them sleep (1-2).  
Thus, minorities in this survey in each country 
admitted to use of codeine containing products for 
relaxant effects. 
The management of family centred stresses tends 
to fall upon women (30) and non-prescription codeine 
containing products provide an accessible destress 
intervention. This can be seen in the two most 
popular products consumed by South Africans which 
were Adco Dol ®, a product used to manage ‘general 
body pain’ with an associated sedative effect and 
Benylin ® which has a sedative effect. Less support 
in South Africa for prescription only may reflect the 
fact that more daily use of these products when 
combined with having to obtain prescription from a 
physician (31), was perceived as adding an 
unacceptable expense to a product perceived as 
relatively benign. 
Availability and easy access to codeine 
containing medicine greatly reinforces perceptions of 
harmlessness and willingness to seek out and use the 
product regularly (4-6).  The majority of respondents 
said they purchased these products in local 
pharmacies.  However, it should be noted that as the 
survey was conducted in community pharmacy 
outlets this sample may be likely to state that they 
purchased these products in the pharmacy and not 
elsewhere (e.g. online). 
In terms of level of regular use, the results of the 
survey were ambiguous; particularly for South Africa 
and England where differences between those who 
took such products regularly on a weekly basis and 
those who used the product less than once a month 
were evenly split. Whilst those using it weekly were 
worryingly high, it is perhaps the higher comparative 
figure for England that is a surprise (bearing in mind 
the socio-economic position of the South Africa 
population is considerably less favourable than in 
England). These results suggest that comparative 
cultural aspects of OTC use need to be further 
examined. This is further reinforced considering the 
substantial difference between England, South Africa 
and Ireland in using combination analgesics, with 
94% of English respondents using these analgesics 
compared to 64% and 55% in Ireland and South 
Africa respectively. 
In all three countries the most commonly bought 
products are amongst those with a high brand 
recognition. These results would appear to give some 
credence to the limited evidence that branding plays 
an important role in consumer choice of medicine 
(22-25).  However, what is striking is that research on 
the relationship between advertising and use of OTC 
products such as Solpadeine is limited. It needs to be 
further examined within the context of people 
developing dependency. 
Insert leaflets are often not consulted by 
consumers and advertising’s role is considerable in 
J Pharm Pharm Sci (www.cspsCanada.org) 21, 286 - 295, 2018 
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terms of information reception (19-21).  Whilst the 
overall results would not necessarily run counter to 
this finding (see Table 2), the survey did indicate that 
this is more nuanced than the literature suggests. 
Thus, for example, women in all three countries were 
more likely to read the insert leaflet than men (though 
not statistically significant). 
There were differences between countries in 
terms of sources of information, with more people in 
England stating they got information from the leaflet; 
whereas more people in South Africa and Ireland said 
they got information from family and friends 
(perhaps reflecting a cultural difference in the 
strength and proximity of family relationships). The 
majority in all three countries indicated that they 
relied on medical professionals and pharmacists for 
advice and information. 
The literature indicates that highly educated 
people are more aware of OTC medicine risks than 
those less educated (4). The survey results appear to 
support this conclusion for Ireland and South Africa. 
However, people in England seem more aware of 
warnings about dangers of codeine containing 
products and that was a statistically significant 
difference. One possible reason for this, other than 
differences in package design in different 
jurisdictions (which would not account for the 
difference with Ireland), might be the way products 
are displayed or again cultural factors as to how 
different societies are socialised to recognise and 
internalise signs of risk/ warnings.  
Just over half of all those surveyed in the three 
countries viewed codeine containing products as a 
safe medication. In Ireland, women were more likely 
to view such products as harmful though this was not 
statistically significant in England and South Africa. 
In England there was an age difference, with older 
people (those over 40) more likely to perceive 
codeine containing products as harmful. This was not 
the case, however, in Ireland and South Africa. These 
results would appear broadly reflective of the 
literature which indicates that people in general do 
not perceive codeine containing products as harmful, 
even though they are aware of their potential dangers 
(4, 13-14, 32).  
Finally, with regards to our samples’ views on 
whether or not to make codeine containing products 
a prescription only medicine there was a considerable 
number of people in Ireland and England who were 
not against this proposition and even in South Africa 
there was majority support. Again, within this 
context a number of features should be noted, 
including that in Ireland and South Africa, the higher 
respondents’ education the more likely they were to 
support this proposition (it should be noted that 
people in England had the highest level of agreement 
that codeine containing products should be a 
prescription only drug, with level of education not 
being a significant factor). The level of disagreement 
with the proposition in South Africa (43%) can be 
seen as aligned with the fact that South Africans were 
the least likely of the three samples to view such 
products as harmful.  Overall, the challenge lies in 
ensuring availability of codeine containing 
medicines for therapeutic use whilst preventing 
dependence and related harms.  Best practices and 
innovations have been identified which focus on the 
products retail lifecycle from manufacture to 
community pharmacy practitioner (33).  These 
innovations warrant further consideration and 
inclusion in regulatory and policy debate in each 
country in order to reduce misuse, dependence and 
related health harms. 
 
Limitations of the study  
This study has several limitations and hence 
interpretations should be treated with some caution. 
A disadvantage of implementing questionnaires, 
which being anonymous and self-reporting reduce 
bias and facilitates honest responses, is that it is 
difficult to establish cause-and-effect conclusions. 
Therefore, demographics outlined in the study may 
not be the proximal reason for some of the chosen 
answers and the results remain descriptive in nature. 
With regards analysis, the decision was taken to use 
parametric tests at times, as these tests furnish 
additional information in relation to the data. In order 
to support this further, chi-square analysis was also 
conducted using the same variables and where only 
the parametric tests were significant, this was 
highlighted. The inability statistically to generalise 
findings due to the sampling method selected is 
recognised as a limitation, although as the study was 
exploratory in nature, it was deemed as the most 
appropriate choice. However, the sample size in each 
of the three sites was of a relatively large size and 
therefore the data being gathered possess a better 
description of the relative characteristics of the 
general population involved in the study. 
 
CONCLUSION 
 
This study aimed to explore comparatively customer 
use, sources of information and knowledge of OTC 
codeine containing medicinal products in three 
countries. In this context, the survey indicates two 
important factors which should be examined in 
further research. The first relates to cultural 
differences in perceptions, knowledge seeking and 
communicating with regard harms and harm 
reduction. It is an issue that one might argue is 
pressing, from a public health perspective. The 
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second area is the issue of gender differences. This 
survey would indicate that women are more likely to 
engage with insert patient leaflets on codeine 
containing products and its potential harms. Bearing 
in mind the significance of women within a family 
context this is an area worth examining in terms of 
how to disseminate information to reduce harms 
more effectively then the literature indicates is 
presently the case. 
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